{"name":"Medicines Evaluation Unit Ltd","slug":"medicines-evaluation-unit-ltd","ticker":"","exchange":"","domain":"medicinesevaluationunit.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fostair pMDI","genericName":"Fostair pMDI","slug":"fostair-pmdi","indication":"Other","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Trimbow pMDI","genericName":"Trimbow pMDI","slug":"trimbow-pmdi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"}]}],"pipeline":[{"name":"Fostair pMDI","genericName":"Fostair pMDI","slug":"fostair-pmdi","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Trimbow pMDI","genericName":"Trimbow pMDI","slug":"trimbow-pmdi","phase":"marketed","mechanism":"Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQNGpiWTFTOXR1VVc0ZUt5bGFvblpVcXYxNnVIazFRdUJPTUYyQWVmNFdrWWVqQk1xRlNCTHE5M1pQZFY3ZVAyQ1RKY2tDMy1oSFQ1VlJmb3kyYlY5ejljUHZ5Y0pxanRIX1czQlAwcl8tR0k1dGt0RDYtQWJaRUEyQWFKVUwtUWZWUndTZVB4SW5IV0hmdENSSlJJZ2ZPRjBjT2lMWEJUQ29JZnFRdmpRZWRYcXpsYXlSX1lxZ05ib2E?oc=5","date":"2026-02-20","type":"pipeline","source":"Fierce Pharma","summary":"Novartis plots sale of India unit while maintaining separate commercial, R&D business in country - Fierce Pharma","headline":"Novartis plots sale of India unit while maintaining separate commercial, R&D business in country","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9zRFhRRy1BQ2ZZQzU5NUU5a1hyZ3JweGlrTnRsd3djMGxJTXNZM3RMLWY1ZEd6bkVzeERVREVTSi1WUHphQXVzTG9CbDFfVk5ZRXFCdVRnZFJXY1ZhNlpmTUs0SDcwY3FucXlUZUJNalRkOU1IX3pr?oc=5","date":"2026-01-26","type":"pipeline","source":"World Health Organization (WHO)","summary":"Essential medicines - World Health Organization (WHO)","headline":"Essential medicines - World Health Organization (WHO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5vbjUxRnpQUVNSOHJuQ0FJdk5MWGp5RTNzX3l1ZXdraXA3Q3hxSC1BZkxYak9MSVV4QmIyQWRNNVVWczJiazNuOHdwSy1XQ181bkZIbmo0a1V5eHhvS09kaVNDTU96U0VDYnVTdjl30gFyQVVfeXFMTVZOQ0l1cGZiQURTR0s2MGV0eUdYcHd3TlpZTll3bXloV18tMF9BSXZfNDIwdDFIeUZkak96c19QZ2w5SlY2bUVlMjAtM004bzRaeXF6MkJPZGxOdTJ3OHRtMGdYSncyWVh4cDBJSjgwMEFR?oc=5","date":"2025-12-26","type":"pipeline","source":"koreabiomed.com","summary":"‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’ - koreabiomed.com","headline":"‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPNnRYMWRRNWdPQWNvTE1IckVaYnRaT3RsX2tEYjk1VTlzZ2lCdkl3Uzg3V0xIc3hKR2p5OE40a0xHN0xLVVFwdW05ODBmTzBVSzJlYlJRbnd4UHk0SkZxSlJPaUhjZWppZEhtcENuODdGN1BuQ3JYN2JtVGMtaHBhNDh1MDFTdzlCbVMyTmlwRDFLYXVxcmIzb2h3V3RpVks1OGFRQg?oc=5","date":"2025-11-18","type":"pipeline","source":"pharmaceutical-journal.com","summary":"How to implement a naloxone supply approach in hospitals - pharmaceutical-journal.com","headline":"How to implement a naloxone supply approach in hospitals - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPck82akxuOUI4YjhjUFQzU0FpbjllQ2RJZ2dKbEE3Zi1fdVJoTFBBNVNBNUJjSkp1Y3V6Nk8ybGRrLWlPbml6VUctbExzZFV6VUMxenE4MDRWQmQ1WFpPUmp6T3VVVFJjVWhzMHpmQkZobE1BSExqN1RmdUkxUGQwcnVDbWVuT2NvVGQyY3padmwxY0x3RmcyV1dWUXJfMWZScWtRa09EYndkTzlxNzAwaTJjTDRHd1BVNmZ0MjIzQi1ta1FQQnc?oc=5","date":"2025-11-11","type":"pipeline","source":"European Medical Journal","summary":"IL-33 Is Not Just IL-33: There Is More Than One Side to the COPD Story - European Medical Journal","headline":"IL-33 Is Not Just IL-33: There Is More Than One Side to the COPD Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOWGNRTXVuLWhwNDlJdFBWSnlKWXB1WlQxQzFQMFFyNnZjdUhhMXlaN3o0ZUNTdmdNTzNMOTFjWDVGYzBXNnZsVlBFMUwyVmdVeE1iTXZKYmpYMmRUcnFQOTI3eE5lV2dybnJfeWRtSEFIa2JiSTkyR3BTb29jZzFWU1VBM25QX08wM09MSnJfbWNDOHZ3YWVMOFFJZHRaY1FuTnc2a0NGRFc?oc=5","date":"2025-11-10","type":"pipeline","source":"evaluate.com","summary":"Evaluate Releases 2030 Forecasts for Global Pharmaceutical Market - evaluate.com","headline":"Evaluate Releases 2030 Forecasts for Global Pharmaceutical Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNY2VwdWJlQVh4V01ZQnB0WjUtOFIzYmpjMW5pWnd0X1FFRXpTZFA3b1NSWlc0Y2pmdUstVS1XMWRSSGN2dWVyMzdVQ0pRelBwMExYRlg4Skk2X2VEelJmbHBib2ZuWElxZ3d4dzc0YjRfMG5obXU1VnFlcW5TUkNhWnJoOTBzcWFFdVJSbmtzYmZqQU0?oc=5","date":"2025-08-06","type":"pipeline","source":"pharmaphorum","summary":"New medicines review process under NHS 10-Year Plan emerges - pharmaphorum","headline":"New medicines review process under NHS 10-Year Plan emerges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1SOEl2emtTZHFndHgwWHQ0NUJRaGFEZ0Z0UmsxMDQzT0ljQklFNWY2elZ3MC1CR3VCejZhTDQ5WlJTeXRoYU9pRG9tbGRJdS15YjI5a3JLSkYzVm45T0NR?oc=5","date":"2025-01-27","type":"pipeline","source":"Nature","summary":"Fully automated in vivo screening system for multi-organ imaging and pharmaceutical evaluation - Nature","headline":"Fully automated in vivo screening system for multi-organ imaging and pharmaceutical evaluation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTC1ENkVrQk1oek5qWVZ4OEVJbU9qcmlHR2w3bVNfQmxhX3pJV2xyYlMxY21JUWZILWw5d0djYjRWNWwyblJ2SENIcDhVQ2M3elBscFZfQ2hLcFN6dklFQnhpZ05tVFItSUk2OUF2N2FBSlJwMVVwQ2F4NWcxRWVkbk90NVFwb3M?oc=5","date":"2024-10-24","type":"trial","source":"Clinical Trials Arena","summary":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions - Clinical Trials Arena","headline":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOTU11QzdwdnZuRmpLRUtXUTltVkdYWGhUVG5hNzdVRjZYRF9EaTdQamNWbmlESXB4QmhZRnQtRTk2NEhzd1owdDItSXFGMTdtS2ZSUEdTRVByNVZ0TnlKc2xHOTJOSVRRRVV0QTNybHc4WnkxaE04VUhlcTRsUXgzY2Z3NHZVWWxnbnFnN3BXMzhkRDEwcGd5NHdicDRSLVVrNEk3SHNjOVN1c29UZTgzOEpEQm13QXEyY3c5a0hTWUtwcnFPNVJ6SlRxTXU3OVNkOWxKdEM0eTVSaXR2bkNDWUg4S0xJOGRwNlpJWW9hSG9zMkxzamV1NW9YYTlac1BuTXN2Nk1EbTdNR3NnVnBOdXUyeHdmcUFsQl8zRHR3cGtNWmZNWUxYTUplemw?oc=5","date":"2024-10-23","type":"trial","source":"businesswire.com","summary":"Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications - businesswire.com","headline":"Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPYkZ6RVNBZ0VBRzVPR0poX05HUzVLUDRQdml0NmhXM0V5VHN2cG03MVdNcjB2SU9nMF8wcGxLTUpPN0k5UGZPS084Z1BwSFZSa1ZOUXh2U09xclRzYU5hZm82RnVIcm5BU0RxVzA1T3l3aWtFd2ZiVmhiWmpNbXVQUjUtbEJzX1k?oc=5","date":"2024-05-15","type":"pipeline","source":"Centers for Disease Control and Prevention | CDC (.gov)","summary":"Pharmacy-Based Interventions to Improve Medication Adherence - Centers for Disease Control and Prevention | CDC (.gov)","headline":"Pharmacy-Based Interventions to Improve Medication Adherence - Centers for Disease Control and Prevention | CDC (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQVTRVcUJZcHU3MnVjNGYzSFFnbldJWFlYX052anZpME1qUUxvLW51LTVpcXhpY2ZvdHliZWk5VTNBaWlRX25YejFIMV9wRFlPQ09sRm9EM2tVaDdTMHV3M1I1UlZ2ek5BQUVkMkJpU0NFQ0dScHlvTEtScWdWYmNpMlpLaUhYRnplTGpLVE93QWNONjg?oc=5","date":"2021-10-10","type":"pipeline","source":"Frontiers","summary":"Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry - Frontiers","headline":"Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}